Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361700 | 1.00 | HMGCR (0.46) | HMGCRLMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6137606 | 1.00 | HMGCR (0.46) | HMGCRLMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL736276 | 0.94 | HMGCR (0.53) | HMGCRLMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28506401 | 0.92 | LMNA (0.44) | HMGCRLMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL9626686 | 0.86 | HMGCR (0.58) | HMGCRLMNAPTPN7 | |
| SCHEMBL12003762 | 0.86 | HMGCR (0.45) | HMGCRALDH1A1TSHRPTPN7 | |
| SCHEMBL6389331 | 0.85 | TSHR (0.48) | HMGCRTSHRPTPN7 | |
| SCHEMBL6389327 | 0.85 | TSHR (0.48) | HMGCRTSHRPTPN7 | |
| SCHEMBL6137410 | 0.83 | HMGCR (0.45) | HMGCRPTPN7 | |
| SCHEMBL6137283 | 0.83 | HMGCR (0.45) | HMGCRPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436252-A4 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-20050020680-A1 | Hydroxyfattysulfonic acid analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-01-27 | — | — | US | disclosed |
| EP-1436252-A1 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024922-A1 | HYDROXYFATTYSULFONIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020680-A1 | Hydroxyfattysulfonic acid analogs | ELANE, HRH2, APEH | HMGCR 725/4885LMNA 3284/4885ALDH1A1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.